Acta Chimica Sinica ›› 2020, Vol. 78 ›› Issue (11): 1260-1267.DOI: 10.6023/A20070285 Previous Articles     Next Articles



董金龙a,b, 沈腊珍a, 文斌a, 宋珍a, 冯俊杰a, 梁钢c, 刘斌b, 杨斌盛b   

  1. a 太原师范学院化学系 晋中 030619;
    b 山西大学分子科学研究所 化学生物学与分子工程教育部重点实验室 太原 030006;
    c 山西医科大学第一医院病理科 太原 030001
  • 投稿日期:2020-07-02 发布日期:2020-09-04
  • 通讯作者: 董金龙, 杨斌盛;
  • 基金资助:

Synthesis of A Novel Anti-diabetes Chromium(III) Complex and Investigation of Its Biological Activity and Mechanism

Dong Jinlonga,b, Shen Lazhena, Wen Bina, Song Zhena, Feng Junjiea, Liang Gangc, Liu Binb, Yang Binshengb   

  1. a Department of Chemistry, Taiyuan Normal University, Jinzhong 030619, China;
    b Institute of Molecular Science, Key Laboratory of Chemical Biology of Molecular Engineering of Education Ministry, Shanxi University, Taiyuan 030006, China;
    c Department of Pathology, First Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2020-07-02 Published:2020-09-04
  • Supported by:
    Project supported by the the National Natural Science Foundation of China (Nos. 21571117, 21701121), the Natural Science Foundation of Shanxi Province (No. 201801D121064), the Science and Technology Innovation Project of Colleges and Universities in Shanxi Province (No. 2019L0818), and the Innovation Project for College Students in Shanxi Province (No. CXCY1905).

In order to search for novel anti-diabetes molecules, phenformin (Phf) was used as precursors to prepare chromium(III) complex [Cr(Phf)3]Cl3 at room temperature. The complex was characterized by elemental analysis (EA), molar conductivity (MC), electrospray ionization mass spectrometry (ESI-MS), infrared (IR), UV-vis and NMR spectroscopy, respectively. In this work, the stability of complex solutions at different temperatures and pH values, reactivity with H2O2 were discussed in detail. The morphology and thermal studies of the complex were also investigated. Meanwhile, C57 diabetic mouse model induced by diet combined with streptozocin (STZ) was established to explore its biological activity from the aspects of fasting blood glucose (FBG), fasting serum insulin (FINS), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) levels, and oral toxicity. Afterwards, in order to explore the biological hypoglycemic mechanism of the complex, the interaction between the complex and glucagon was studied at (37±0.5) ℃ in Phosphate Buffer Saline (PBS) buffer at pH 7.4 by fluorescence spectra, which the conditional binding constant K is 1.29×105 L·mol-1, and the number of binding sites n is about 1. As a result, the interaction between the complex and glucagon was static quenching. The complex which retained the glucose-lowering properties of Phf exhibited good physical and chemical properties, beneficial function on blood glucose and lipid metabolism for Type II Diabetes mellitus (T2DM). The glucose-lowering mechanism of the complex was proposed, and the multi-functional application of metal complex in glucose-lowering and lipid-controlling was also achieved. Furthermore, oral toxicity results showed that the complex had no toxicity on all organs of mice. Methyl Thiazolyl Tetrazolium (MTT) assays also showed that the complex exhibited lower cytotoxicity than the positive control CrCl3 and Phf. Taken together, these results demonstrated that the non-toxic [Cr(Phf)3]Cl3 complex might be a potential candidate for novel anti–diabetic drug development. It may also provide a new idea for the prevention and treatment of type 2 diabetes.

Key words: chromium(III) phenformin, diabetes, biology activity, glucagon, toxicity